AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21069355 — intervention group
Group type: EXPERIMENTAL
Intervention: Early feeding group (EFG) - oral liquid diet on the first postoperative day, advanced to regular diet within 24 hours as tolerated.
Number of subjects: 54
Study 21069355 — intervention group
Group type: COMPARATOR
Intervention: Traditional care group - nothing per orus until elimination of first flatus, then oral liquid diet followed by regular diet within 24 hours.
Number of subjects: 54
Study 21069355 — intervention group
Group type: EXPERIMENTAL
Intervention: Early feeding group (EFG)
Number of subjects: 54
Study 21069355 — intervention group
Group type: COMPARATOR
Intervention: Traditional care group
Number of subjects: 54
Study 21069355 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 54
Study 19060285 — intervention group
Group type: COMPARATOR
Intervention: SITA Standard
Number of subjects: 60
Study 19060285 — intervention group
Group type: EXPERIMENTAL
Intervention: GATE-i
Number of subjects: 60
Study 19060285 — intervention group
Group type: EXPERIMENTAL
Intervention: GATE
Number of subjects: 60
Study 19060285 — intervention group
Group type: COMPARATOR
Intervention: Full-Threshold (FT)
Number of subjects: 60
Study 17413628 — intervention group
Group type: COMPARATOR
Intervention: Local dry cold application
Number of subjects: 40
Study 17413628 — intervention group
Group type: COMPARATOR
Intervention: EMLA cream application
Number of subjects: 40
Study 17413628 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold application and EMLA cream application
Number of subjects: 40
Study 14592675 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. nicotine
Number of subjects: 18
Study 14592675 — intervention group
Group type: EXPERIMENTAL
Intervention: denicotinized cigarette smoke
Number of subjects: 18
Study 14592675 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. nicotine and denicotinized smoke puffs
Number of subjects: 18
Study 14592675 — intervention group
Group type: EXPERIMENTAL
Intervention: denicotinized smoke
Number of subjects: 18
Study 14592675 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. nicotine and denicotinized smoke
Number of subjects: 18
Study 10802893 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.625 mg conjugated estrogens and 2.5 mg medroxyprogesterone acetate
Number of subjects: 0
Study 10802893 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8820551 — intervention group
Group type: EXPERIMENTAL
Intervention: Judicially monitored mental health treatment
Number of subjects: 96
Study 8820551 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 96
Study 1483491 — intervention group
Group type: EXPERIMENTAL
Intervention: ANP‐270 0.3 micrograms/kg
Number of subjects: 40
Study 1483491 — intervention group
Group type: EXPERIMENTAL
Intervention: ANP‐270 1.5 micrograms/kg
Number of subjects: 40
Study 1483491 — intervention group
Group type: EXPERIMENTAL
Intervention: ANP‐270 3.0 micrograms/kg
Number of subjects: 40
Study 1483491 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 2860162 — intervention group
Group type: EXPERIMENTAL
Intervention: Povidone-iodine lubricating gel (PVP-I)
Number of subjects: 30
Study 2860162 — intervention group
Group type: COMPARATOR
Intervention: Control (K-Y lubricating jelly)
Number of subjects: 30
Study 29070503 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise training (60-70% peak oxygen uptake for 45 min, 3 days/week for 8 weeks)
Number of subjects: 52
Study 29070503 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise training
Number of subjects: 52
Study 26317375 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 26
Study 26317375 — intervention group
Group type: EXPERIMENTAL
Intervention: Metabolic Activator Blend (MAB)
Number of subjects: 26
Study 25008853 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E supplementation (400 IU every other day)
Number of subjects: 14641
Study 25008853 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C supplementation (500 mg daily)
Number of subjects: 14641
Study 25008853 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14641
Study 22017475 — intervention group
Group type: EXPERIMENTAL
Intervention: Trans-apical LV lead implantation
Number of subjects: 23
Study 22017475 — intervention group
Group type: COMPARATOR
Intervention: Epicardial LV lead implantation
Number of subjects: 23
Study 20467801 — intervention group
Group type: EXPERIMENTAL
Intervention: Assisted zona thinning (group 1A)
Number of subjects: 4
Study 20467801 — intervention group
Group type: COMPARATOR
Intervention: Not-thinned control (group 1B)
Number of subjects: 4
Study 20467801 — intervention group
Group type: EXPERIMENTAL
Intervention: Assisted zona thinning (group 2A)
Number of subjects: 4
Study 20467801 — intervention group
Group type: COMPARATOR
Intervention: Not-thinned control (group 2B)
Number of subjects: 4
Study 17700424 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus GG (LGG) powder containing 60 million cells, twice daily for a minimum period of 7 days
Number of subjects: 235
Study 17700424 — intervention group
Group type: COMPARATOR
Intervention: Oral rehydration solution (ORS) alone
Number of subjects: 235
Study 16282839 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 0
Study 16282839 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 12131247 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiorespiratory fitness (VO2peak)
Number of subjects: 30
Study 10505821 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil 400 mg
Number of subjects: 481
Study 10505821 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 481
Study 8951255 — intervention group
Group type: EXPERIMENTAL
Intervention: Prenatal pediatric visits
Number of subjects: 156
Study 8951255 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 156
Study 2254222 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindamycin (300 mg qid for one day)
Number of subjects: 8
Study 2254222 — intervention group
Group type: COMPARATOR
Intervention: Control (no clindamycin)
Number of subjects: 8
Study 7357803 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol 40 mg every 8 hr for 1 wk
Number of subjects: 21
Study 7357803 — intervention group
Group type: EXPERIMENTAL
Intervention: Acebutolol 300 mg every 8 hr for 1 wk
Number of subjects: 21
Study 7357803 — intervention group
Group type: COMPARATOR
Intervention: Placebo every 8 hr for 1 wk
Number of subjects: 21
Study 31785165 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab
Number of subjects: 0
Study 28115517 — intervention group
Group type: EXPERIMENTAL
Intervention: Renal denervation plus stepped-care antihypertensive treatment
Number of subjects: 97
Study 28115517 — intervention group
Group type: COMPARATOR
Intervention: Control group (stepped-care treatment alone)
Number of subjects: 97
Study 26283629 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil supplementation
Number of subjects: 50
Study 26283629 — intervention group
Group type: COMPARATOR
Intervention: Placebo (olive oil)
Number of subjects: 50
Study 24438478 — intervention group
Group type: EXPERIMENTAL
Intervention: Universal screening for GDM in primary care (n=392)
Number of subjects: 784
Study 24438478 — intervention group
Group type: COMPARATOR
Intervention: Universal screening for GDM in secondary care (n=392)
Number of subjects: 784
Study 24438478 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary care screening
Number of subjects: 784
Study 24438478 — intervention group
Group type: COMPARATOR
Intervention: Secondary care screening
Number of subjects: 784
Study 22212110 — intervention group
Group type: EXPERIMENTAL
Intervention: Endobronchial ultrasound-guide sheath (EBUS-GS)
Number of subjects: 64
Study 22212110 — intervention group
Group type: COMPARATOR
Intervention: Computed tomography (CT)-guided percutaneous core biopsy
Number of subjects: 64
Study 22212110 — intervention group
Group type: COMPARATOR
Intervention: CT-guided biopsy for lesions <2 cm
Number of subjects: 64
Study 19757270 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual misoprostol (2 tabs of 200 microg)
Number of subjects: 100
Study 19757270 — intervention group
Group type: COMPARATOR
Intervention: Intravenous oxytocin (20 units at 10 cc/min)
Number of subjects: 100
Study 19757270 — intervention group
Group type: COMPARATOR
Intervention: Intravenous oxytocin
Number of subjects: 100
Study 19757270 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual misoprostol
Number of subjects: 100
Study 17311834 — intervention group
Group type: EXPERIMENTAL
Intervention: Nesiritide
Number of subjects: 40
Study 17311834 — intervention group
Group type: COMPARATOR
Intervention: Milrinone
Number of subjects: 40
Study 15316789 — intervention group
Group type: EXPERIMENTAL
Intervention: Ability to stand on one foot
Number of subjects: 1166
Study 15316789 — intervention group
Group type: EXPERIMENTAL
Intervention: Ability to squat down to touch the floor
Number of subjects: 1166
Study 15316789 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-assessed health ('very good' vs 'moderate' or poorer state of health)
Number of subjects: 1166
Study 11394404 — intervention group
Group type: EXPERIMENTAL
Intervention: PTFE-based flosses
Number of subjects: 27
Study 11394404 — intervention group
Group type: COMPARATOR
Intervention: Nylon-based flosses
Number of subjects: 27
Study 11394404 — intervention group
Group type: COMPARATOR
Intervention: Nylon-based tape
Number of subjects: 27
Study 9492965 — intervention group
Group type: EXPERIMENTAL
Intervention: ICD prophylaxis
Number of subjects: 900
Study 9492965 — intervention group
Group type: COMPARATOR
Intervention: No therapy (control)
Number of subjects: 900
Study 7893589 — intervention group
Group type: EXPERIMENTAL
Intervention: Racemic mephenytoin coadministered with debrisoquine
Number of subjects: 106
Study 7893589 — intervention group
Group type: EXPERIMENTAL
Intervention: Racemic mephenytoin coadministered with sparteine
Number of subjects: 106
Study 7893589 — intervention group
Group type: EXPERIMENTAL
Intervention: Racemic mephenytoin
Number of subjects: 106
Study 7893589 — intervention group
Group type: EXPERIMENTAL
Intervention: Debrisoquine and sparteine metabolic ratios
Number of subjects: 106
Study 2920499 — intervention group
Group type: EXPERIMENTAL
Intervention: Yohimbine (4 mg t.i.d.)
Number of subjects: 12
Study 2920499 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 74014 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholestyramine
Number of subjects: 22
Study 74014 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 22
Study 31117864 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexor carpi ulnaris to biceps motor branch transfer
Number of subjects: 91
Study 31117864 — intervention group
Group type: COMPARATOR
Intervention: Control group (randomly selected)
Number of subjects: 91
Study 31117864 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative flexor carpi ulnaris weakness (M<5)
Number of subjects: 91
Study 27894929 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound disposable gastroscopy (TDG)
Number of subjects: 48
Study 27894929 — intervention group
Group type: COMPARATOR
Intervention: Conventional gastroscopy (CG)
Number of subjects: 48
Study 25516462 — intervention group
Group type: EXPERIMENTAL
Intervention: LLETZ-cone
Number of subjects: 103
Study 25516462 — intervention group
Group type: COMPARATOR
Intervention: SWETZ
Number of subjects: 103
Study 23916321 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadone
Number of subjects: 80
Study 23916321 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine-naloxone
Number of subjects: 80
Study 23916321 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 80
Study 21247415 — intervention group
Group type: EXPERIMENTAL
Intervention: Rye products (RK)
Number of subjects: 10
Study 21247415 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole grain rye (RK)
Number of subjects: 10
Study 21247415 — intervention group
Group type: EXPERIMENTAL
Intervention: Rye products and WK
Number of subjects: 10
Study 21247415 — intervention group
Group type: EXPERIMENTAL
Intervention: Rye kernels (RK)
Number of subjects: 10
Study 21247415 — intervention group
Group type: EXPERIMENTAL
Intervention: Rye products
Number of subjects: 10
Study 21247415 — intervention group
Group type: EXPERIMENTAL
Intervention: High content of indigestible carbohydrates in breakfast products
Number of subjects: 10
Study 21247415 — intervention group
Group type: EXPERIMENTAL
Intervention: High breath H(2) (AUC 120-270 min)
Number of subjects: 10
Study 20003300 — intervention group
Group type: EXPERIMENTAL
Intervention: Health coaching, home blood pressure monitoring, and home-titration of antihypertensive medications
Number of subjects: 300
Study 20003300 — intervention group
Group type: COMPARATOR
Intervention: Health coaching plus home blood pressure monitoring
Number of subjects: 300
Study 20003300 — intervention group
Group type: COMPARATOR
Intervention: Usual care (passive control group)
Number of subjects: 300
Study 17258357 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumococcal protein D conjugate vaccine
Number of subjects: 0
Study 17258357 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 16150956 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactulose (30 g)
Number of subjects: 8
Study 16150956 — intervention group
Group type: COMPARATOR
Intervention: Saline solution
Number of subjects: 8
Study 14658595 — intervention group
Group type: EXPERIMENTAL
Intervention: Colour Doppler ultrasound with contrast agents
Number of subjects: 72
Study 10606362 — intervention group
Group type: EXPERIMENTAL
Intervention: Mannequin tender and swollen joint counts
Number of subjects: 60
Study 10606362 — intervention group
Group type: EXPERIMENTAL
Intervention: RADAR tender and swollen joint counts
Number of subjects: 60
Study 10606362 — intervention group
Group type: EXPERIMENTAL
Intervention: RADAR swollen joint counts
Number of subjects: 60
Study 7740055 — intervention group
Group type: EXPERIMENTAL
Intervention: Triazolam (0.125 or 0.25 mg per capsule)
Number of subjects: 6
Study 7740055 — intervention group
Group type: EXPERIMENTAL
Intervention: Triazolam (0.0312-0.25 mg per capsule)
Number of subjects: 6
Study 7740055 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimenter-administered doses of triazolam
Number of subjects: 6
Study 7740055 — intervention group
Group type: EXPERIMENTAL
Intervention: Same day ratings obtained while subjects were under the influence of triazolam
Number of subjects: 6
Study 2289489 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyridostigmine (30 mg)
Number of subjects: 8
Study 2289489 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 2289489 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyridostigmine
Number of subjects: 8
Study 7023592 — intervention group
Group type: EXPERIMENTAL
Intervention: Physostigmine 0.375 mg
Number of subjects: 11
Study 7023592 — intervention group
Group type: EXPERIMENTAL
Intervention: Arecoline 4 mg
Number of subjects: 11
Study 7023592 — intervention group
Group type: EXPERIMENTAL
Intervention: Physostigmine 0.25 mg
Number of subjects: 11
Study 7023592 — intervention group
Group type: EXPERIMENTAL
Intervention: Physostigmine 0.75 mg
Number of subjects: 11
Study 7023592 — intervention group
Group type: EXPERIMENTAL
Intervention: Arecoline 2 mg
Number of subjects: 11
Study 7023592 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 11
Study 31018173 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-step stannous fluoride dentifrice and hydrogen peroxide whitening gel system, interactive oscillating-rotating electric toothbrush, and expanded polytetrafluoroethylene floss
Number of subjects: 52
Study 31018173 — intervention group
Group type: COMPARATOR
Intervention: Standard sodium fluoride dentifrice and a manual toothbrush (Control)
Number of subjects: 52
Study 26604072 — intervention group
Group type: COMPARATOR
Intervention: Finerenone 1-40 mg PEG solution
Number of subjects: 60
Study 26604072 — intervention group
Group type: COMPARATOR
Intervention: Finerenone 10 mg IR tablet
Number of subjects: 60
Study 26604072 — intervention group
Group type: EXPERIMENTAL
Intervention: Finerenone 80 mg (eight × finerenone 10 mg IR tablets)
Number of subjects: 60
Study 24654350 — intervention group
Group type: EXPERIMENTAL
Intervention: Incremental sevoflurane induction method
Number of subjects: 100
Study 24654350 — intervention group
Group type: COMPARATOR
Intervention: Fixed 8% sevoflurane induction method
Number of subjects: 100
Study 22408123 — intervention group
Group type: EXPERIMENTAL
Intervention: GH treatment (0.01 mg/kg per day for the first week, 0.02 mg/kg per day for the second week, and 0.03 mg/kg per day for the third week)
Number of subjects: 12
Study 22408123 — intervention group
Group type: COMPARATOR
Intervention: Pegvisomant treatment (10 mg/day for the first week and 15 mg/day for the last two weeks)
Number of subjects: 12
Study 20188634 — intervention group
Group type: EXPERIMENTAL
Intervention: Levetiracetam (LEV)
Number of subjects: 95
Study 20188634 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenobarbital (PB)
Number of subjects: 95
Study 20188634 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine (LTG)
Number of subjects: 95
Study 20188634 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 95
Study 18520979 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetrabenazine (TBZ) treatment withdrawal
Number of subjects: 30
Study 18520979 — intervention group
Group type: COMPARATOR
Intervention: Partial or no withdrawal of TBZ treatment
Number of subjects: 30
Study 18520979 — intervention group
Group type: EXPERIMENTAL
Intervention: Post hoc analysis of TBZ withdrawal
Number of subjects: 30
Study 16135901 — intervention group
Group type: EXPERIMENTAL
Intervention: Efavirenz 600 mg daily
Number of subjects: 84
Study 16135901 — intervention group
Group type: EXPERIMENTAL
Intervention: Efavirenz 800 mg daily
Number of subjects: 84
Study 16135901 — intervention group
Group type: COMPARATOR
Intervention: Both groups (600 mg and 800 mg)
Number of subjects: 84
Study 12374927 — intervention group
Group type: EXPERIMENTAL
Intervention: RSA RoekoSeal with laterally compacted gutta-percha (Group 1)
Number of subjects: 80
Study 12374927 — intervention group
Group type: EXPERIMENTAL
Intervention: RSA RoekoSeal with vertically compacted warm gutta-percha (Group 2)
Number of subjects: 80
Study 12374927 — intervention group
Group type: COMPARATOR
Intervention: Pulp Canal Sealer (Group 3)
Number of subjects: 80
Study 12374927 — intervention group
Group type: COMPARATOR
Intervention: No sealer (Group 4)
Number of subjects: 80
Study 11019950 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 microgram ethinyl estradiol combined with 150 microgram desogestrel (DSG/EE)
Number of subjects: 241
Study 11019950 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 microgram ethinyl estradiol combined with 75 microgram gestodene (GSD/EE)
Number of subjects: 241
Study 7586338 — intervention group
Group type: EXPERIMENTAL
Intervention: Lovastatin (20 mg/d, titrated to 40 and then to 80 mg during the first 16 weeks)
Number of subjects: 62
Study 7586338 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 2175083 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone and glycerol
Number of subjects: 102
Study 2175083 — intervention group
Group type: COMPARATOR
Intervention: Lasix
Number of subjects: 102
Study 2175083 — intervention group
Group type: COMPARATOR
Intervention: Mannitol+
Number of subjects: 102
Study 7021057 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal dental treatment)
Number of subjects: 25
Study 7021057 — intervention group
Group type: EXPERIMENTAL
Intervention: Test group (additional fortnightly professional prophylaxes)
Number of subjects: 25
Study 7021057 — intervention group
Group type: EXPERIMENTAL
Intervention: Test + F group (prophylaxes plus fortnightly 2-min fluoride rinses)
Number of subjects: 25
Study 31755431 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral propranolol 1 mg/kg/day titrated to 3 mg/kg/day over 1 week, continued for 6 months and tapered over 1 week
Number of subjects: 20
Study 31755431 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralesional propranolol hydrochloride 1 mg/ml; 0.2 ml/cm, 3 doses 4-6 weeks apart
Number of subjects: 20
Study 31755431 — intervention group
Group type: COMPARATOR
Intervention: Comparison between both groups
Number of subjects: 20
Study 28258844 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical aortic valve replacement (SAVR)
Number of subjects: 52
Study 28258844 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter aortic valve replacement (TAVR)
Number of subjects: 52
Study 26116264 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal injection of ranibizumab
Number of subjects: 57919
Study 26116264 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal injection of bevacizumab
Number of subjects: 57919
Study 26116264 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal anti-VEGF medications (ranibizumab and bevacizumab)
Number of subjects: 57919
Study 26116264 — intervention group
Group type: COMPARATOR
Intervention: Control group following cataract surgery
Number of subjects: 57919
Study 23778060 — intervention group
Group type: EXPERIMENTAL
Intervention: ECIG group (experienced EC users)
Number of subjects: 80
Study 23778060 — intervention group
Group type: COMPARATOR
Intervention: SM-S group (smokers smoking tobacco cigarettes)
Number of subjects: 80
Study 23778060 — intervention group
Group type: COMPARATOR
Intervention: SM-E group (smokers using EC)
Number of subjects: 80
Study 21846439 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen cream (3 g of vaginal cream containing 1.875 g of conjugated estrogens for six weeks)
Number of subjects: 69
Study 21846439 — intervention group
Group type: COMPARATOR
Intervention: Placebo cream (comparable cream without estrogens for six weeks)
Number of subjects: 69
Study 19210012 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Adherence and Depression (CBT-AD), 10 to 12 sessions
Number of subjects: 0
Study 19210012 — intervention group
Group type: COMPARATOR
Intervention: Enhanced Treatment as Usual (ETAU), single-session intervention
Number of subjects: 0
Study 19210012 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Adherence and Depression (CBT-AD)
Number of subjects: 0
Study 16424720 — intervention group
Group type: EXPERIMENTAL
Intervention: Semirecumbent position (target backrest elevation of 45 degrees)
Number of subjects: 221
Study 16424720 — intervention group
Group type: COMPARATOR
Intervention: Supine position (backrest elevation of 10 degrees)
Number of subjects: 221